Actively Recruiting
Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)
Led by Cancer Commons · Updated on 2026-02-13
300
Participants Needed
1
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Many FDA-approved drugs are not available to patients with a particular cancer because there has been no successful clinical trial conducted for that drug against that cancer. In the absence of such a successful clinical trial, the drug is not included in the National Comprehensive Cancer Network (NCCN) guidelines list of approved drugs for that cancer. The absence of a drug in the NCCN Guidelines for a particular cancer is usually not an indication that the drug has been shown to be ineffective for patients with that cancer. Rather, it is an indication that there is insufficient clinical trial evidence to include it. A drug that is FDA-approved for one or more cancers but is not in the NCCN Guidelines for a particular cancer is called an "off-guideline" drug for that cancer. This study is being done to measure and compare the reliability of multiple different treatment selection tests to predict a participant's response to an off- guideline cancer therapy. The results can guide oncologists to effective off-guideline drugs that would otherwise not be available to their advanced cancer patients. As this is an observational study, all the data gathered and analyzed will be generated in the normal practice of medicine, not by the study.
CONDITIONS
Official Title
Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant must have a valid genomic or functional test or be willing to undergo a new test
- Analysis of the participant's test must produce a set of Promising Off-guideline Drug(s)
- Oncologist must be willing to administer one or more Promising Off-guideline Drug(s)
- The study team must have an approved method of paying for the administered Off-Guideline Drug(s), such as health insurance or self-pay
- Participant must sign the Informed Consent
You will not qualify if you...
- No set of Promising Off-guideline Drug(s) identified
- Oncologist not willing to administer one or more Promising Off-guideline Drug(s)
- No approved method of paying for the administered off-guideline Drug(s)
- No signed Informed Consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Commons
Palo Alto, California, United States, 94306
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here